12,412 Shares in Supernus Pharmaceuticals, Inc. $SUPN Purchased by EntryPoint Capital LLC

Key Points

• EntryPoint Capital LLC purchased a new stake in Supernus Pharmaceuticals, acquiring 12,412 shares valued at approximately $406,000 in the first quarter.
• Supernus Pharmaceuticals' stock has a market capitalization of $2.39 billion and is currently trading around $42.68, with analysts giving it a consensus rating of "Moderate Buy."
• Insider trading included substantial sales by directors, with a total of 152,826 shares sold recently, indicating a shift in ownership among company insiders.

EntryPoint Capital LLC purchased a new stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 12,412 shares of the specialty pharmaceutical company's stock, valued at approximately $406,000.

Several other institutional investors and hedge funds also recently modified their holdings of the business. GW&K Investment Management LLC lifted its holdings in shares of Supernus Pharmaceuticals by 14.6% in the first quarter. GW&K Investment Management LLC now owns 1,382,441 shares of the specialty pharmaceutical company's stock valued at $45,275,000 after purchasing an additional 176,091 shares in the last quarter. Northern Trust Corp lifted its holdings in shares of Supernus Pharmaceuticals by 18.3% in the fourth quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock valued at $25,933,000 after purchasing an additional 110,867 shares in the last quarter. Ashford Capital Management Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 0.3% in the fourth quarter. Ashford Capital Management Inc. now owns 545,775 shares of the specialty pharmaceutical company's stock valued at $19,735,000 after purchasing an additional 1,740 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 33.5% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 545,658 shares of the specialty pharmaceutical company's stock valued at $19,731,000 after purchasing an additional 136,870 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Supernus Pharmaceuticals by 4.4% in the first quarter. Invesco Ltd. now owns 530,631 shares of the specialty pharmaceutical company's stock valued at $17,378,000 after purchasing an additional 22,562 shares in the last quarter.

Analyst Upgrades and Downgrades

SUPN has been the topic of several recent analyst reports. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald upped their price objective on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an "overweight" rating in a research note on Wednesday, August 6th. Finally, Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Two analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.

Supernus Pharmaceuticals Stock Up 3.6%

Shares of Supernus Pharmaceuticals stock traded up $1.56 during trading hours on Friday, hitting $44.88. The company's stock had a trading volume of 1,047,668 shares, compared to its average volume of 1,064,514. The business has a fifty day moving average of $35.41 and a 200 day moving average of $33.69. Supernus Pharmaceuticals, Inc. has a 1-year low of $29.16 and a 1-year high of $45.01. The company has a market capitalization of $2.52 billion, a PE ratio of 39.03 and a beta of 0.74.

Insiders Place Their Bets

In other news, Director Bethany Sensenig sold 5,369 shares of the company's stock in a transaction dated Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jack A. Khattar sold 140,000 shares of the firm's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the sale, the chief executive officer owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. The trade was a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 152,826 shares of company stock worth $6,424,773 over the last quarter. 8.80% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.